Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

159.69
4,765,963

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew

Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic and Smith & Nephew

    Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up

    Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.

      Drug/Biotech Stocks Q3 Earnings on Oct 25: AMGN, GSK, VRTX

      The pharma/biotech industry has seen a solid start to Q3 earnings as evident from J&J's encouraging results. Let's see if some of the other leading players - Amgen, Glaxo and Vertex - follow suit.

        Centene (CNC) Tops Q3 Earnings & Revenues, Raises '17 View

        Centene's (CNC) strong third-quarter earnings were driven by solid revenue growth.

          Sheraz Mian headshot

          Earnings Picture Further Improves

          It's not news that corporate earnings are good, but this earnings season is spotlighting two incrementally new positives to the earnings backdrop.

            Healthcare ETF (VHT) Hits New 52-Week High

            Healthcare ETF hits a new 52-week high amid strong earnings and talks of bipartisan deal.

              Swarup Gupta headshot

              Dow 30 Stock Roundup: AmEx, IBM, JNJ, Goldman Beat

              The Dow experienced substantial gains over this week, powered primarily by strong earnings expectations and bullish results.

                Healthcare ETFs Head to Head: XLV vs. VHT

                Head to head comparison of two Healthcare ETFs, XLV and VHT.

                  Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings

                  Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.

                    Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?

                    Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.

                      Varian Medical (VAR) Initiates Halcyon Treatment in Europe

                      Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.

                        Sanghamitra Saha headshot

                        Dow ETFs Soar as the Index Hits 23,000

                        Dow Jones Industrial Average hits 23,000 and benefits these ETFs.

                          Stock Market News For Oct 18, 2017

                          Benchmarks finished higher on Tuesday after a slew of strong corporate earnings led gains for healthcare stocks.

                            J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

                            J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

                              Market: Spectacular All Around

                              Market: Spectacular All Around

                                Mark Vickery headshot

                                Q3 Earnings Blasting Off: GS, MS, JNJ and More

                                Stronger-than-expected earnings are providing a good tonic for us this morning, even as pre-markets are mixed at this hour.

                                  J&J (JNJ) Beats on Q3 Earnings & Sales, Ups 2017 View

                                  Johnson & Johnson (JNJ) beat consensus estimate for both earnings and sales and also raised its 2017 sales and profit outlook.

                                    Tracey Ryniec headshot

                                    5 Earnings All Stars to Start Off the Week

                                    Nervous about earnings season? This week, it pays to check in with these bellwether stocks.

                                      J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use

                                      Johnson & Johnson (JNJ) announced approval of label expansion for its plaque psoriasis drug, Stelara, to include adolescent patients.

                                        MedTech Players Eyeing Emerging Market Growth Opportunities

                                        The gloomy eco-political scenario in the United States and Europe points toward the fact that emerging geographies are playing a crucial role in the growth of the MedTech space globally.

                                          J&J (JNJ) to Kickstart Pharma Q3 Earnings: What's in Store?

                                          J&J's (JNJ) sales and earnings growth are expected to accelerate in third and fourth quarters. The company expects organic sales growth of 4% in the second half of the year.

                                            Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit

                                            Pfizer (PFE) is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin-off, sale or other transaction.

                                              Sweta Killa headshot

                                              Will Dow ETFs Continue to Shine in Q3 Earnings?

                                              The Dow Jones has returned 24.2% since the Election Day compared to a gain of 18.9% for the S&P 500.

                                                Here's What's Has Happened in the HCV Space Lately

                                                A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.

                                                  Johnson & Johnson Files sNDA for Label Expansion of Invokana

                                                  Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.